Last reviewed · How we verify

Levobupivacaine wound infusion

University of Genova · FDA-approved active Small molecule

Levobupivacaine wound infusion is a Local anesthetic Small molecule drug developed by University of Genova. It is currently FDA-approved for Postoperative wound pain management via local infiltration.

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission at the wound site.

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission at the wound site. Used for Postoperative wound pain management via local infiltration.

At a glance

Generic nameLevobupivacaine wound infusion
SponsorUniversity of Genova
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain management / Anesthesia
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine, a long-acting amide local anesthetic. When infused into wound tissue, it penetrates nerve cell membranes and reversibly blocks voltage-gated sodium channels, preventing depolarization and propagation of action potentials. This results in local anesthesia and analgesia at the surgical wound site, reducing postoperative pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levobupivacaine wound infusion

What is Levobupivacaine wound infusion?

Levobupivacaine wound infusion is a Local anesthetic drug developed by University of Genova, indicated for Postoperative wound pain management via local infiltration.

How does Levobupivacaine wound infusion work?

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission at the wound site.

What is Levobupivacaine wound infusion used for?

Levobupivacaine wound infusion is indicated for Postoperative wound pain management via local infiltration.

Who makes Levobupivacaine wound infusion?

Levobupivacaine wound infusion is developed and marketed by University of Genova (see full University of Genova pipeline at /company/university-of-genova).

What drug class is Levobupivacaine wound infusion in?

Levobupivacaine wound infusion belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Levobupivacaine wound infusion in?

Levobupivacaine wound infusion is FDA-approved (marketed).

What are the side effects of Levobupivacaine wound infusion?

Common side effects of Levobupivacaine wound infusion include Local tissue irritation, Systemic toxicity (if absorbed in high concentrations), Allergic reaction.

What does Levobupivacaine wound infusion target?

Levobupivacaine wound infusion targets Voltage-gated sodium channels and is a Local anesthetic.

Related